1. Trang chủ
  2. » Giáo Dục - Đào Tạo

Real world evidence of trade, test, isolated and quanrantine impact on covid 19 pademic response performance

18 18 0

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 18
Dung lượng 1,43 MB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

These were: proportion of quarantined population “Q-proportion” among newly diagnosed COVID-19 cases/week, ratio of quarantined people to cases, and ratio of negative tests to new cases,

Trang 1

Real world evidence of trace, test, isolation, and quarantine impact on the COVID-19

pandemic response performance

Juhwan Oh1, Seung-sik Hwang2*, Khuong Quynh Long3, Minkyung Kim4, Kunhee Park5, Seunghyun Kwon6,

Osvaldo Enrique Artaza Barrios7, Irene Torres8, Matthew M Kavanagh9, Naoki Kondo10, S Patrick Kaucher11,

Hoang Van Minh12, Dong Roman Xu13, Mikael Rostila14, Caroline Benski15, Mellissa Withers16, Borwornsom

Leerapan17, Myoungsoon You2, Cristiani Vieira Machado18, Chang-Chuan Chan19, Hwa-Young Lee20, Jeonghyun

Shin1, Hyejin Jeong21, Sung-In Kim22, Soon Ae Kim4, Soo Kyung Park23, Judith McCool24, Lawrence O Gostin9,

S.V Subramanian20, Jeffrey F Markuns25 27, Yun-Chul Hong1 27, Chris Bullen24 27, Jong-Koo Lee 1 27, Martin

McKee26 27

1Seoul National University College of Medicine, Seoul, Republic of Korea

2Seoul National University Graduate School of Public Health, Seoul, Republic of Korea

3Hasselt University, Hasselt, Belgium

4Korea Foundation for International Healthcare, Seoul, Republic of Korea

5Gyunggi Province in Suwon, Republic of Korea

6Korea Disease Control and Prevention in Osong, Republic of Korea

7The University of the Americas in Santiago, Chile

8Fundacion Octaedro in Quito, Ecuador,

9Georgetown University in Washington, D.C USA

10Kyoto University School of Public Health in Kyoto, Japan

11Mailman School of Public Health, Columbia University in New York, USA

12Hanoi University of Public Health, Hanoi, Vietnam

13Southern Medical University in Guangzhou, Guangdong, China

14Stockholm University in Stockholm, Sweden

15University Hospital of Geneva, Geneva, Switzerland

16University of Southern California in Los Angeles, CA, USA

17Mahidol University Faculty of Medicine Ramathibodi Hospital in Bangkok, Thailand

18Oswaldo Cruz Foundation in Rio de Janeiro, Brazil

19National Taiwan University School of Public Health, Taipei, Taiwan

20Harvard T H Chan School of Public Health, Boston, MA, USA

21Seoul National University Hospital, Seoul, Republic of Korea

22Daegu Correctional Institution in Dagegu, Republic of Korea

23National Health Insurance Research Institute in Wonju, Republic of Korea

Preprint not peer reviewed

Trang 2

24The University of Auckland School of Population Health, Auckland, New Zealand

25Boston University School of Medicine, Boston, MA, USA

26London School of Hygiene and Tropical Medicine, London, UK

27These authors contributed equally as co-senior authors

*Corresponding author:

Dr Seung-sik Hwang

cyberdoc@snu.ac.kr

Seoul National University Graduate School of Public Health, Seoul, Republic of Korea

Preprint not peer reviewed

Trang 3

There is continuing uncertainty about the effectiveness of testing, tracing, isolation, and quarantine (TTIQ) policies

during the pandemic

Methods

We developed proxy indicators of the implementation of TTIQ policies at subnational and national (Republic of

Korea), and international level (111 countries) from the beginning of 2020 to September 2021 These were:

proportion of quarantined population (“Q-proportion”) among newly diagnosed COVID-19 cases/week, ratio of

quarantined people to cases, and ratio of negative tests to new cases, with higher values suggesting more complete

TTIQ We used linear regression to analyze the association between TTIQ indicators and 1-week lagged cases and

cumulative deaths, separating periods before and after vaccines becoming available

Findings

We found consistently inverse associations between TTIQ indicators and COVID-19 outcomes, with gradual

attenuation as vaccination coverage rose Q-proportion overall (β= -0·091; p-value < 0·001) and log-transformed

quarantined population per case (β ranges from -0·626; p < 0.001 to -0·288; p= 0·023) in each of 9 provinces were

negatively associated with log-transformed 1-week lagged incidence in Korea overall The strength of association

decreased with greater vaccination coverage The ratio of negative test results/new case was also inversely

associated with incidence (β= -1·19; p-value < 0·001) in Korea Globally, increasing negative test ratio was

significantly associated with lower cumulative cases and deaths per capita, more so earlier in the pandemic

Jurisdictions with lower vaccination coverage showed the strongest association

Interpretation

A real-world evaluation demonstrates an association between performance of testing, contact tracing, isolation, and

quarantine and better disease outcomes

Funding

Ministry of Foreign Affairs, Republic of Korea

Preprint not peer reviewed

Trang 4

In many countries the focus of responses to COVID-19 changed in 2021 as vaccination and, to a lesser extent,

advances in therapeutics taking center stage.(1,2) The attractions are obvious The non-pharmaceutical interventions

(NPI) that proved so effective early in the pandemic(3,4) involved widespread social disruption, economic hardship,

and collateral damage to health services.(5,6) Yet this new approach has struggled to cope with the Delta variant,

even in those few countries that have achieved high rates of vaccine roll out.(7) Meanwhile, in large parts of the

world the prospect of achieving high vaccination rates remains a distant hope, for many reasons, reflecting problems

of both supply,(8)with inadequate production, a consequence in part of policies on intellectual property,(9)and

inequitable distribution,(10) and of demand, including weak health system infrastructure, vaccine hesitancy,(11) and

concerted campaigns of disinformation.(12) Even if high levels of global coverage could be achieved rapidly,

waning vaccine effectiveness and the emergence of new variants of concern capable of evading immunity induced

by current vaccines or past infection have challenged the hope that the first generation of vaccines would be the

‘magic bullet’.(13,14) Further outbreaks are inevitable(15) and NPIs will remain an essential part of the

armamentarium of policy responses.(16–19)

NPIs can be divided into general and targeted The former, affecting everyone living in a particular area, include

stay-at-home orders and school closures The latter apply to individuals and their contacts, based on testing, contact

tracing, and isolation and quarantine (TTIQ) The latter approach can be effective in certain circumstances without

the need for generalized restrictions, as seen in the 1918 influenza pandemic.(20) Yet, while previously

unimaginable advances in surveillance and testing should have made targeted approaches easier than in the past,

many countries have opted for generalized restrictions when cases rose.(21)

There are many reasons why this happened but, most often, it was because the capacity to implement TTIQ was

inadequate or overwhelmed This is apparent in countries where it worked, at least initially, as in New Zealand,

Vietnam, Taiwan, and Singapore).(22–25) They “bought time” by imposing generalized restrictions early, in some

cases helped by having invested substantially in preparedness following their experience with SARS in 2003 In

other countries, such as the United States, United Kingdom, and some countries in Western Europe, the initial

restrictions were delayed, with even a few days having major consequences, exacerbated by underinvestment in

preparedness and, in some, specific policy failures.(26,27) In others, particularly middle- and low-income countries

facing resource constraints, weak public health capacity, and in particular ability to undertake mass testing,(28)

limited what was possible

It is, however, only fair to recognize that policymakers faced with the threat of a pandemic were in a difficult

position It was not obvious how effective TTIQ would be and, even now, evaluations are limited, often based on

experience in particular settings, such as the U.S state of Oregon or Guangzhou in China.(4) There is thus an urgent

need to assess the effectiveness of TTIQ in limiting pandemic spread To this end, we have examined the

association between cumulative COVID-19 cases and deaths and the implementation of TTIQ interventions, taking

account of vaccination coverage, beginning with the experience of one country, the Republic of Korea, and

extending our analysis, to the extent possible given data availability, in 111 jurisdictions worldwide

Method

Study population and data The first analysis, of Korea, used three different data sources, the publicly available

national dataset from by Seoul National University Asia Research Center sourced from the Korean Disease Control

Agency: 1) cumulative COVID-19 cases, 2) deaths, 3) vaccinated people, and 4) number of negative test results of

Korea; the authors’ curation of 5) daily numbers of quarantined population per case from the daily reports of the

nine provincial governments, that report numbers quarantined; and the authors’ curation of 6) the proportion of the

quarantined population among newly diagnosed COVID-19 cases per week (“Q-proportion”) reporting from the

Korean Disease Control and Prevention Agency(29) which is publicly available every Monday The international

data covered 111 jurisdictions using three sets of publicly available data: cumulative COVID-19 cases, 2) deaths and

3) vaccinated people per million in each jurisdiction population retrieved from the dataset curated by Our World in

Data,(30) which is sourced from multiple national databases by the Center for Systems Science and Engineering at

Johns Hopkins University

Preprint not peer reviewed

Trang 5

Variables Independent variables We used three proxy or latent variables to estimate the implementation of TTIQ

If the system is working well, the number of people tested and quarantined per case will be high as will the

proportion of negative tests (as a very high positivity rate suggests that true cases are being missed) In the national

analysis, where we had the most granular data, we first used the proportion of the quarantined population among

newly diagnosed COVID-19 cases per week This was based on the hypothesis that the greater the completeness of

tracing, the greater the proportion of newly confirmed cases that will be found among traced-quarantined population Conversely, when tracing is incomplete most newly confirmed cases will not occur among the quarantined

population Second, based on our hypothesis that more effective tracing would generate a greater number of

quarantined people for each newly confirmed case, we used the daily log-transformed number of quarantined people

per newly confirmed case at provincial level In both the national and global analysis, we used the log-transformed

country-specific ratio of cumulative negative tests per case as a proxy for effective TTIQ implementation on the

assumption that a more proactive tracing policy generates more negative test results per newly confirmed case

Outcome variables We used as our outcome measure the 1-week lagged newly confirmed cases per million for

national level and per thousand people for provincial level analysis of Korea For the global analysis we used the

cumulative number of new cases per million population, and the cumulative number of deaths per million population

in each country All outcome variables were log-transformed

Analyses In the national analysis, we examined associations between the 1-week lagged number of confirmed cases

per unit population (outcome variable) and each of the three proxy latent variables of TTIQ as independent

variables In the global analysis, we examined associations between the cumulative number of deaths per million

population (log) and number of negative tests per case (log) and the number of negative tests per case (negative test

results ratio); and associations between the cumulative number of deaths per million population (log) and number of

negative tests per case (log) We performed a subgroup analysis by designating an early phase (2020) and a late

phase (2021), based on when vaccines became available

For the Korean data analysis, reflecting data availability, we conducted three analyses First, we analyzed data from

the week of October 3rd-9th, 2020 through the week of September 12th-18th, 2021 for the Q-proportion As the

independent variable, we regressed the publicly available weekly Q-proportion with the outcome variable, which

was expressed as 7-day averaged daily COVID-19 cases by million, lagged by 1 week, and log transformed (Figure

1) Second, we analyzed the data from July 1, 2021 through September 14, 2021 for the quarantine analysis (the nine provinces) For the independent variable, we divided the daily numbers of quarantine population by the newly

confirmed COVID-19 cases (“Quarantined population per case ratio”), then we divided the ratio by 14 to account

for the mandatory 2 week quarantine period enforced by the Korean government, and finally log transformed the

ratio For the outcome variable, we divided daily COVID-19 cases by one thousand, lagged the values by 1 week,

and finally log transformed the values We divided nine provinces into two categories: (A) higher and (B) lower

vaccination coverage (Figure 2A, 2B, and supplementary table) Third, we analyzed the data from Feb 22 (100th case day), 2020 through Sep 16, 2021 for testing For the independent variable, we divided the number of negative tests

by the newly confirmed case, and log transformed the values For the outcome variable, we divided daily COVID-19 cases by million, lagged the values by 1 week, and finally log transformed the values (Figure 3)

The period for global analysis for negative test ratio was Jan 1, 2020 through Sep 16, 2021 For the independent

variable, we divided the number of negative tests by the newly confirmed case (“Negative test results ratio”), and

log transformed the ratio For the outcome variable, we divided the cumulative number of COVID-19 cases and

deaths by million, lagged the values by 1 week, and finally log transformed the values We divided 111 jurisdictions

into a tertile based on the vaccine coverage per million population (Figure 5)

We used linear regression analysis in Stata 17 software (StataCorp 2021 Stata Statistical Software: Release 17

College Station, TX: StataCorp LLC.): Level of significance with P=0.05

Results

In the national analysis the Q-proportions ranging between 29·9 and 66·4 %, were negatively associated with the

log-transformed 1-week lagged new case incidence per million population (β= -0·091; p-value < 0·001) during the

period Oct 3-9, 2020, to Sep 12-18, 2021 (Figure 1) The log transformed quarantined population per newly

confirmed case (range 5 to 33 quarantined people per case (mean) in each province) was also negatively associated

Preprint not peer reviewed

Trang 6

with the log transformed 1-week lagged confirmed new daily cases in the 9 Korean provinces, of which Seoul

(population vaccination rate rank 6 of 9 provinces with 50% coverage) showed the largest association (β = -0·626;

p-value < 0·001), the province with the lowest vaccinated population (47·7%) showed the 2nd largest association

(β= -0·603; p-value < 0·001), whereas the province with the most vaccinated population (58.3%) showed the

smallest association (β= -0·288; p-value = 0·023 during the period July 1, 2021 to September 14, 2021 (Figure 2;

supplementary table) The magnitude of the inverse associations was attenuated when vaccination coverage rates

were increased (β = -1·253; p-value < 0·001) The log-transformed ratio of negative test results per daily confirmed

new case (ranging from 7 to 2981 negative test results per case) were also inversely associated with the 1-week

lagged incidence of cases per million-unit population (β= -1·22 p-value < 0·001) during the period of Feb 22, 2020

to Sep 16, 2021 (Figure 3)

Turning to the global analysis, Figure 4 shows the distribution of cumulative cases or deaths per million population

for each country against the ratio of cumulative negative tests per case in 2020 and 2021 The highest negative test

ratio was in China (1890) at the end of 2020 and in Hong Kong (5573) at the end of 2021, while the lowest was in

Brazil in both periods, respectively The association between the negative test ratio (log) and cumulative cases per

population (log) in the global analyses were all significantly negative in all periods and both the early and the late

period subgroups The association was stronger for cumulative deaths (Figure 5A) than cumulative cases (Figure

5B) With cumulative deaths (Figure 5A), the association in the early phase was stronger (β= -0·95 (95% CI: -1·15

to -0·75); p < 0.001) than in the later phase (β= -0·60 (95% CI: -0·80 to -0·40); p < 0·001) A similar pattern was

found with cumulative cases (Figure 5B): the association in the early phase was stronger (β= -0·77 (95% CI: -0·96

to -0·57); p < 0·001) than in the later phase (β= -0·31 (95% CI: -0·50 to -0·12); p < 0·001) Consistently inverse

associations with gradual attenuation were found when the analysis was stratified by periods before and after

vaccines became available — in 2021, jurisdictions in the lowest tertile of vaccination coverage showed a stronger

inverse association (β= -1·51 (95% CI: -2·07 to -0·94); p < 0·001) than the highest tertile (β= -0·81 (95% CI: -1·11

to -0·51); p < 0·001), with a similar pattern in COVID-19 incidence (Figure 5C)

Discussion

Our study has some important limitations, most related to the validity of the data Especially in the global analysis,

we are dependent on the coverage, quality, and consistency of the data Early in the pandemic, the ability to track

incidence was limited by testing capacity everywhere and, even now, this remains the case in many places

Notwithstanding guidance from WHO, there are national differences in how deaths are attributed to COVID-19,(31)

as well as gaps in surveillance coverage in many parts of the world(29,32) and even, in some countries, possible data falsification.(33) This analysis does not allow us to isolate the TTIQ impact from the many other variables that

influence COVID-19 responses: i.e behavioral characteristics such as adherence to physical distancing and face

covering guidelines as well as indoor ventilation use and performance However, given the complex nature of these

relationships the analytic challenges of disentangling these factors would be formidable even if data on the omitted

variables were available

These results suggest that proactive implementation of TTIQ is associated with both reduced numbers of COVID-19

cases and deaths across multiple countries The greater Q-proportion (an indicator of effective contact-tracing), the

lower the 1-week lagged incidence A higher number of quarantined people per new case and a higher negative test

ratio were also associated with fewer cases one week later Globally, a higher negative test results ratio was

associated with fewer cumulative deaths and cases, in both 2020 and 2021 In a further analysis limited to the period

when vaccines became available, in 2021, it appears that TTIQ was more effective in countries unable to reach high

vaccination rates (noting that while these tended to be poorer countries with less testing capacity many also had

lower COVID burdens) The value of TTIQ was sustained, even as vaccine roll out has proceeded in both analyses

Our results support the value of TTIQ even with increasing vaccination rates, a finding that is likely to assume

greater importance should new variants with greater vaccine escape become widespread and because of likely

political unwillingness to impose further large-scale lockdowns in many countries, especially given evidence that the latter vary in their effectiveness.(34)

Conclusion

Preprint not peer reviewed

Trang 7

We provide empirical evidence of the effectiveness of TTIQ in reducing cases and deaths using a real-world

evaluation, offering support for continued investment in the capacity to implement these measures However, further

studies, such as that using the Korean data above, are needed to corroborate our findings, linked to mixed methods

studies to understand how best to implement this approach in different contexts

Preprint not peer reviewed

Trang 8

References

1 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al Safety and Efficacy of the

BNT162b2 mRNA Covid-19 Vaccine N Engl J Med 2020 Dec 31;383(27):2603–15

2 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al Efficacy and Safety of the mRNA-1273

SARS-CoV-2 Vaccine N Engl J Med 2021 Feb 4;384(5):403–16

3 Lee J-K, Bullen C, Ben Amor Y, Bush SR, Colombo F, Gaviria A, et al Institutional and behaviour-change

interventions to support COVID-19 public health measures: a review by the Lancet Commission Task Force on

public health measures to suppress the pandemic Int Health 2021 Sep 3;13(5):399–409

4 Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al Effectiveness of isolation, testing,

contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a

mathematical modelling study Lancet Infect Dis 2020 Oct;20(10):1151–60

5 Mansfield KE, Mathur R, Tazare J, Henderson AD, Mulick AR, Carreira H, et al Indirect acute effects of the

COVID-19 pandemic on physical and mental health in the UK: a population-based study Lancet Digit Health

2021 Apr;3(4):e217–30

6 Douglas M, Katikireddi SV, Taulbut M, McKee M, McCartney G Mitigating the wider health effects of

covid-19 pandemic response BMJ 2020 Apr 27;369:m1557

7 Baraniuk C Covid-19: How effective are vaccines against the delta variant? BMJ 2021 Aug 9;374:n1960

8 Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al Challenges in

ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment Lancet

Lond Engl 2021 Mar 13;397(10278):1023–34

9 Jecker NS, Atuire CA What’s yours is ours: waiving intellectual property protections for COVID-19 vaccines

J Med Ethics 2021 Sep;47(9):595–8

10 Hyder AA, Hyder MA, Nasir K, Ndebele P Inequitable COVID-19 vaccine distribution and its effects Bull

World Health Organ 2021 Jun 1;99(6):406-406A

11 Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al A global survey of potential

acceptance of a COVID-19 vaccine Nat Med 2021 Feb;27(2):225–8

12 The HART Files: Inside the Group Trying to Smuggle Anti-Vaccine Myths into Westminster [Internet] 2021

[cited 2021 Sep 24] Available from: https://www.logically.ai/articles/hart-files-anti-vaccine-myths-westminster

13 Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al Effectiveness of Pfizer-BioNTech and

Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During

Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network,

March 1-August 1, 2021 MMWR Morb Mortal Wkly Rep 2021 Aug 27;70(34):1163–6

14 Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al Effectiveness of Covid-19

Vaccines against the B.1.617.2 (Delta) Variant N Engl J Med 2021 Aug 12;385(7):585–94

15 Iftekhar EN, Priesemann V, Balling R, Bauer S, Beutels P, Calero Valdez A, et al A look into the future of the

COVID-19 pandemic in Europe: an expert consultation Lancet Reg Health Eur 2021 Sep;8:100185

16 Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ Vaccination and non-pharmaceutical interventions for

COVID-19: a mathematical modelling study Lancet Infect Dis 2021 Jun;21(6):793–802

Preprint not peer reviewed

Trang 9

17 Yang J, Marziano V, Deng X, Guzzetta G, Zhang J, Trentini F, et al Despite vaccination, China needs

non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021 Nat Hum Behav 2021

Aug;5(8):1009–20

18 Gozzi N, Bajardi P, Perra N The importance of non-pharmaceutical interventions during the COVID-19

vaccine rollout PLoS Comput Biol 2021 Sep;17(9):e1009346

19 Contreras S, Dehning J, Mohr SB, Bauer S, Spitzner FP, Priesemann V Low case numbers enable long-term

stable pandemic control without lockdowns Sci Adv 7(41):eabg2243

20 Markel H, Lipman HB, Navarro JA, Sloan A, Michalsen JR, Stern AM, et al Nonpharmaceutical interventions

implemented by US cities during the 1918-1919 influenza pandemic JAMA 2007 Aug 8;298(6):644–54

21 Perra N Non-pharmaceutical interventions during the COVID-19 pandemic: A review Phys Rep 2021 May

23;913:1–52

22 Baker MG, Wilson N, Anglemyer A Successful Elimination of Covid-19 Transmission in New Zealand N

Engl J Med 2020 Aug 20;383(8):e56

23 Nguyen TV, Tran QD, Phan LT, Vu LN, Truong DTT, Truong HC, et al In the interest of public safety: rapid

response to the COVID-19 epidemic in Vietnam BMJ Glob Health 2021 Jan;6(1):e004100

24 Summers J, Cheng H-Y, Lin H-H, Barnard LT, Kvalsvig A, Wilson N, et al Potential lessons from the Taiwan

and New Zealand health responses to the COVID-19 pandemic Lancet Reg Health West Pac 2020

Nov;4:100044

25 Leung K, Wu JT The gradual release exit strategy after lockdown against COVID-19 Lancet Reg Health West

Pac 2020 Aug;1:100008

26 Lewis D Why many countries failed at COVID contact-tracing - but some got it right Nature 2020

Dec;588(7838):384–7

27 Chung S-C, Marlow S, Tobias N, Alogna A, Alogna I, You S-L, et al Lessons from countries implementing

find, test, trace, isolation and support policies in the rapid response of the COVID-19 pandemic: a systematic

review BMJ Open 2021 Jun 29;11(7):e047832

28 Torres I, Sippy R, Sacoto F Assessing critical gaps in COVID-19 testing capacity: the case of delayed results

in Ecuador BMC Public Health 2021 Apr 1;21(1):637

29 The Korean Disease Control and Prevention Agency [Internet] [cited 2021 Oct 1] Available from:

http://kdca.go.kr

30 Coronavirus Pandemic (COVID-19) [Internet] Our World in Data 2020 Available from:

https://ourworldindata.org/coronavirus

31 Karanikolos M, McKee M How comparable is COVID-19 mortality across countries? EuroHealth 2020;6

32 Sempé L, Lloyd-Sherlock P, Martínez R, Ebrahim S, McKee M, Acosta E Estimation of all-cause excess

mortality by age-specific mortality patterns for countries with incomplete vital statistics: a population-based

study of the case of Peru during the first wave of the COVID-19 pandemic Lancet Reg Health – Am [Internet]

2021 Aug 20 [cited 2021 Sep 25];0(0) Available from:

https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(21)00031-4/fulltext

33 Kilani A An interpretation of reported COVID-19 cases in post-Soviet states J Public Health Oxf Engl 2021

Jun 7;43(2):e409–10

Preprint not peer reviewed

Trang 10

34 Oh J, Lee H-Y, Khuong QL, Markuns JF, Bullen C, Barrios OEA, et al Mobility restrictions were associated

with reductions in COVID-19 incidence early in the pandemic: evidence from a real-time evaluation in 34

countries Sci Rep 2021 Jul 2;11(1):13717

Preprint not peer reviewed

Ngày đăng: 09/02/2022, 10:14

TÀI LIỆU CÙNG NGƯỜI DÙNG

TÀI LIỆU LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm

w